October 14, 2015
ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, has announced that Joan W. Miller, MD, Chair of the Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, is one of five of the world’s premier retinal disease thought leaders who will serve on its newly formed scientific advisory board (SAB). The goal of the SAB is to help guide development of novel vision protection technology in age-related macular degeneration (AMD) and retinal detachment.